Feline Toxoplasmosis: Risks to Pregnant Women and Immunocompromised Individuals

Etiology and Life Cycle

Toxoplasmosis is caused by the obligate intracellular protozoan parasite Toxoplasma gondii, a member of the phylum Apicomplexa [1]. Felids, including domestic cats, serve as the definitive hosts for T. gondii, meaning that sexual reproduction occurs exclusively within the feline intestinal epithelium [1, 2]. This unique biological feature places cats at the center of the parasite's transmission ecology [3]. The life cycle involves three infectious stages: tachyzoites (rapidly dividing forms), bradyzoites (slowly dividing forms contained within tissue cysts), and sporozoites (contained within sporulated oocysts) [1, 4].

Cats become infected through predation of intermediate hosts (e.g., rodents, birds) containing tissue cysts, or through ingestion of sporulated oocysts from the environment [4, 5]. Following ingestion, bradyzoites or sporozoites excyst in the small intestine and invade enterocytes, initiating the enteroepithelial cycle [1, 2]. This cycle culminates in the production of unsporulated oocysts, which are shed in the feces [3]. Shedding typically begins 3 to 10 days post-infection and can last for 1 to 3 weeks, during which millions of oocysts may be excreted [6, 4]. Oocysts sporulate and become infectious in the environment within 1 to 5 days, depending on temperature and humidity [1]. Sporulated oocysts are highly resilient and can remain viable in soil and water for months to years [1, 3].

Epidemiology and Seroprevalence

Feline toxoplasmosis is distributed globally, with seroprevalence rates varying widely by geographic region, cat population (domiciled versus stray), and management practices [7, 8, 9]. A seroprevalence study in Kuwait reported that 60% of sampled cats were positive for anti-T. gondii IgG antibodies, while 31.7% were positive for IgM antibodies [7]. In Greece, a nationwide study of 1554 cats found an overall seroprevalence of 21.8% using a rapid immunochromatographic test [8]. Risk factors significantly associated with seropositivity in that study included rural habitat, outdoor access, and hunting behavior [8]. In Brazil, seroprevalence in Teresina, Piauí, was reported at 57.14% among cats with ocular lesions [10]. A study in Finland documented a seroprevalence of 46.7% in client-owned cats [11]. In the United States, early surveys using the Sabin-Feldman dye test found antibodies in 37.5% of adult domiciled cats and 57.9% of adult stray cats [6]. These data underscore the high environmental exposure of feline populations to T. gondii [7, 8, 6].

Clinical Signs in Cats

Most immunocompetent cats infected with T. gondii remain asymptomatic [12, 13]. Clinical disease, when it occurs, is most often associated with the extraintestinal (tachyzoite) phase and can affect multiple organ systems [13, 14]. Common clinical signs include fever, anorexia, lethargy, and weight loss [13, 15]. Respiratory signs such as dyspnea and hyperpnea are frequently observed due to pneumonitis [15]. Ocular toxoplasmosis is a well-documented manifestation, presenting as anterior uveitis, posterior segment involvement (chorioretinitis), or both [10]. In a study of 60 seropositive cats with ocular signs, 63.33% had anterior uveitis and 20% had posterior segment involvement [10]. Neurological signs, including ataxia, seizures, and behavioral changes, can result from cerebral toxoplasmosis [14, 16]. Hepatic involvement may lead to icterus and elevated liver enzyme activities [17, 15].

Immunocompromised cats, particularly those co-infected with feline immunodeficiency virus (FIV) or feline leukemia virus (FeLV), are at significantly higher risk for severe, disseminated toxoplasmosis [18, 15, 19, 16]. A case report described fatal disseminated toxoplasmosis in an FIV-positive cat receiving oclacitinib for feline atopic skin syndrome [18]. Co-infection with feline coronavirus (FCoV) has also been associated with more severe disease, including anemia, neutrophilia, and elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities [17].

Pathology

The pathological lesions of feline toxoplasmosis reflect the cytolytic nature of tachyzoite replication [14]. In the lungs, interstitial pneumonia with necrosis and infiltration of mononuclear cells is common [14]. Hepatic lesions include multifocal necrosis and periportal inflammation [17, 14]. In the central nervous system, necrotizing encephalitis with glial nodules and perivascular cuffing is observed [14, 16]. Ocular pathology includes granulomatous chorioretinitis and anterior uveitis [10]. Tissue cysts containing bradyzoites are often found in the brain, skeletal muscle, and myocardium, and these represent the chronic stage of infection [4, 14].

Diagnostics

Accurate diagnosis of feline toxoplasmosis is critical for both clinical management and public health surveillance [1, 20]. Diagnostic approaches include serological, molecular, and parasitological methods [1].

Serological Assays

Serological detection of anti-T. gondii antibodies (IgG and IgM) is the most commonly used diagnostic approach [1, 7, 20]. Commercial enzyme-linked immunosorbent assay (ELISA) kits and rapid immunochromatographic assays are widely available [1, 7, 8]. The latex agglutination test (LAT) has been used as a reference method in some studies [21]. Detection of IgM antibodies suggests recent infection or reactivation, while IgG antibodies indicate past exposure [20]. However, serological interpretation in cats is complicated by the fact that many infected cats are asymptomatic and may have persistent IgG titers [20].

Recent research has focused on improving serological specificity by using recombinant antigens [2, 22, 21]. The micronemal protein MIC17A, which is abundantly expressed in merozoites (the enteroepithelial stage), has been identified as a promising diagnostic marker for feline toxoplasmosis [2, 22]. In contrast, antigens highly expressed in tachyzoites (e.g., GRA1, MIC3) show poor reactivity with feline IgG antibodies [2]. A combination of recombinant antigens including SAG2 and dense granule proteins (GRA2, GRA6, GRA7, GRA15) has demonstrated diagnostic performance comparable to tachyzoite lysate antigen (TLA) in IgG ELISA, with concordance and kappa values of 94.27% and 0.81, respectively [21].

Molecular Methods

Polymerase chain reaction (PCR) assays targeting T. gondii DNA (e.g., the B1 gene or 529 bp repeat element) are used for detection of the parasite in blood, aqueous humor, cerebrospinal fluid, bronchoalveolar lavage fluid, and tissue biopsies [1]. PCR is particularly useful for confirming active infection and for diagnosing ocular and cerebral toxoplasmosis [1, 10]. Quantitative PCR (qPCR) can provide information on parasite burden [1].

Parasitological Methods

Direct microscopic examination of feces for oocysts is possible during the acute shedding period, but sensitivity is low due to intermittent shedding and morphological similarity to other coccidian oocysts (e.g., Isospora spp.) [6, 23]. Bioassay in mice or cats is considered the gold standard for detecting infectious T. gondii in tissues, but this method is impractical for routine clinical use [1, 6].

Emerging Technologies

Nanomaterial-enhanced biosensors and artificial intelligence (AI) driven diagnostic algorithms are being explored to improve sensitivity, specificity, and stage-specific detection of T. gondii infection in cats [1]. These technologies aim to identify antigens expressed during schizogony, bradyzoite, and sporulated oocyst stages, which are critical for early detection [1].

Treatment

Treatment of clinical feline toxoplasmosis is aimed at reducing tachyzoite replication [12, 10, 24]. The standard therapeutic protocol involves a combination of clindamycin (10-12 mg/kg orally every 12 hours for 2-4 weeks) or a sulfonamide-diaminopyrimidine combination (e.g., sulfadiazine-trimethoprim) [12, 10, 24]. In a study of 60 cats with ocular toxoplasmosis, 46.7% showed complete response, 41.7% showed partial response, and 11.6% showed poor response to treatment [10]. Immunocompetent cats generally respond favorably, while immunocompromised cats (e.g., those with FIV or FeLV co-infection) have a poorer prognosis [18, 15]. Supportive care, including fluid therapy and nutritional support, is often necessary [12].

Control and Prevention

Control of feline toxoplasmosis centers on reducing environmental contamination with oocysts and preventing infection in cats [1, 3, 25]. Key measures include:

• Preventing cats from hunting intermediate hosts (e.g., rodents, birds) by keeping them indoors [8, 26].
• Feeding cats only cooked or commercially processed food, never raw meat [8, 26].
• Daily removal and proper disposal of cat feces to prevent oocyst sporulation [3].
• Pregnant women and immunocompromised individuals should avoid cleaning litter boxes. If unavoidable, gloves and a mask should be worn, and the litter box should be cleaned daily [3, 25].
• Covering children's sandboxes to prevent cat defecation [3].

Zoonotic Risk: Cat Toxoplasmosis Baby and Immunocompromised Individuals

The primary public health concern associated with feline toxoplasmosis is the risk of congenital transmission in pregnant women and severe disease in immunocompromised individuals [1, 2, 3]. The term "cat toxoplasmosis baby" reflects the well-documented risk of vertical transmission when a woman acquires a primary T. gondii infection during pregnancy [2, 3]. Tachyzoites can cross the placenta and infect the fetus, potentially leading to abortion, stillbirth, or congenital anomalies including hydrocephalus, intracranial calcifications, and chorioretinitis [2, 3].

Immunocompromised individuals, including those with HIV/AIDS, organ transplant recipients, and patients receiving immunosuppressive therapy, are at risk for reactivation of latent toxoplasmosis, which can manifest as life-threatening encephalitis, pneumonitis, or disseminated disease [1, 2, 18]. The risk of zoonotic transmission from cats is primarily through accidental ingestion of sporulated oocysts from contaminated environments (e.g., litter boxes, soil, sandboxes) [3, 25]. Direct contact with an infected cat is not considered a significant risk, as cats shed oocysts only for a limited period and oocysts require sporulation to become infectious [3, 6].

flowchart TD
    A[Cat ingests T. gondii cysts/oocysts], > B[Enteroepithelial cycle in small intestine]
    B, > C[Oocyst shedding in feces]
    C, > D[Oocyst sporulation in environment 1-5 days]
    D, > E[Human exposure via contaminated soil, litter, food, water]
    E, > F{Pregnant woman}
    E, > G{Immunocompromised individual}
    F, > H[Congenital toxoplasmosis: abortion, stillbirth, fetal anomalies]
    G, > I[Reactivation: encephalitis, pneumonitis, disseminated disease]
    B, > J[Tachyzoite dissemination to tissues]
    J, > K[Chronic infection: tissue cysts in brain, muscle]
    K, > L[Reactivation in immunocompromised cats]

Conclusion

Feline toxoplasmosis is a zoonotic disease of significant public health importance due to the role of cats as definitive hosts for T. gondii [1, 2, 3]. Accurate diagnosis in cats, using serological and molecular methods, is essential for identifying active infections and informing control strategies [1, 21]. The development of stage-specific diagnostic markers, such as MIC17A, represents a significant advance in feline diagnostics [2, 22]. Prevention of environmental contamination with oocysts, through responsible pet ownership and hygiene practices, remains the cornerstone of reducing zoonotic risk to pregnant women and immunocompromised individuals [3, 25].

References

[1] Dan Zhao, Yanzhen Liao, Hao Liu et al. Comprehensive diagnostic approaches to feline toxoplasmosis: Bridging traditional methods and emerging technologies. Virulence, 2025. URL: https://www.semanticscholar.org/paper/2e757aa2ddd10827f80fab2653e009ad1d5e71da

[2] Jinling Chen, Lilan Xue, Hongxia Hu et al. MIC17A is a novel diagnostic marker for feline toxoplasmosis. Animal Diseases, 2022. URL: https://www.semanticscholar.org/paper/409a1c77abdc8102e0ee7ad5b4a222f8efdd3e71

[3] K. Bresciani, A. L. Galvão, A. L. D. Vasconcellos et al. EPIDEMIOLOGICAL ASPECTS OF FELINE TOXOPLASMOSIS. Journal, 2016. URL: https://www.semanticscholar.org/paper/6b9f21d91d91295b742aef77632d2525479580ce

[4] J. P. Dubey, J. K. Frenkel. Feline toxoplasmosis from acutely infected mice and the development of Toxoplasma cysts. The Journal of Protozoology, 1976. URL: https://www.semanticscholar.org/paper/8baf73ffc19ee8034b04927ed5eb249b3daa9e18

[5] Y. Omata, H. Oikawa, M. Kanda et al. Experimental feline toxoplasmosis: humoral immune responses of cats inoculated orally with Toxoplasma gondii cysts and oocysts. Nihon Juigaku Zasshi. The Japanese Journal of Veterinary Science, 1990. URL: https://www.semanticscholar.org/paper/b51652947e0dfa715c4d08df67cd76221708e926

[6] J. Dubey. Feline toxoplasmosis and coccidiosis: a survey of domiciled and stray cats. Journal of the American Veterinary Medical Association, 1973. URL: https://www.semanticscholar.org/paper/ccb8d11ca9bbfc79aec59433b8a97df0159136cd

[7] S. M. Ibrahim, I. Mohamed, S. E. Suliman et al. Seroprevalence of Feline Toxoplasmosis in Kuwait State. International Journal of Current Microbiology and Applied Sciences, 2025. URL: https://www.semanticscholar.org/paper/f05f6b05b012c996ed244740c03869e7e95c3f5b

[8] G. Sioutas, I. Symeonidou, A. Gelasakis et al. Feline Toxoplasmosis in Greece: A Countrywide Seroprevalence Study and Associated Risk Factors. Pathogens, 2022. URL: https://www.semanticscholar.org/paper/7a38aa6feab78b556c75fca605f426eadd8440c6

[9] J. Teixeira, Jéssica S Oliveira, D. Almeida et al. Seroprevalence of feline toxoplasmosis in Teresina, Piauí, Brazil. Journal, 2016. URL: https://www.semanticscholar.org/paper/b5a75e8076e477c63e0ad3cf290165adcea31440

[10] K. M. Ali, A. M. Abu-Seida, M. Abuowarda. Feline ocular toxoplasmosis: seroprevalence, diagnosis and treatment outcome of 60 clinical cases. Polish Journal of Veterinary Sciences, 2021. URL: https://www.semanticscholar.org/paper/0d19fc80bf1bde129d6b11a3e14b5e0b7dc7192c

[11] P. Jokelainen, O. Simola, E. Rantanen et al. Feline toxoplasmosis in Finland. Journal of Veterinary Diagnostic Investigation, 2012. URL: https://www.semanticscholar.org/paper/6a4fbacb25ee047707fcc3cc04c3c600dc321216

[12] S. Caney. Update on feline toxoplasmosis. Journal, 2021. URL: https://www.semanticscholar.org/paper/04388a62c4aa2e740b6e424bd443e7a1366da8e7

[13] M. Lappin, C. Greene, S. Winston et al. Clinical Feline Toxoplasmosis. Journal, 1989. URL: https://www.semanticscholar.org/paper/1ae2d5c4420cf0ff662e99d9964dc6c34a70036b

[14] R. Hirth, S. W. Nielsen. Pathology of feline toxoplasmosis. Journal of Small Animal Practice, 1969. URL: https://www.semanticscholar.org/paper/70ea7aed2b1cd57cf4238050c1395234eaa98dde

[15] E. A. Okewole, M. O. Akpan. Clinical feline toxoplasmosis: parasitological, haematological and serological findings in retroviral infected and uninfected cats. Journal, 2002. URL: https://www.semanticscholar.org/paper/2e27851bb71e0ccb0409282c54991b0237af3d91

[16] L. Zandonà, R. Brunetta, C. Zanardello et al. Cerebral toxoplasmosis in a cat with feline leukemia and feline infectious peritonitis viral infections. The Canadian Veterinary Journal, 2018. URL: https://www.semanticscholar.org/paper/9b883ef30868dedf42a1c8dc0e77da44dfe0abb2

[17] S. Savoyskaya, A. Sanin, I. Ogorodnikova et al. Phosprenyl usage as part of the complex therapy of feline chronic coronavirus infection complicated by toxoplasmosis. Russian Veterinary Journal, 2022. URL: https://www.semanticscholar.org/paper/d2205256d3e3592683ec54c4e85a619eac09add0

[18] A. Moore, A. Burrows, R. Malik et al. Fatal disseminated toxoplasmosis in a feline immunodeficiency virus-positive cat receiving oclacitinib for feline atopic skin syndrome. Veterinary Dermatology, 2022. URL: https://www.semanticscholar.org/paper/c931267329077e9f22210c3439872dddff053542

[19] A. Munhoz, Samir Batista Hage, R. Cruz et al. Toxoplasmosis in cats in northeastern Brazil: Frequency, associated factors and coinfection with Neospora caninum, feline immunodeficiency virus and feline leukemia virus. Veterinary Parasitology: Regional Studies and Reports, 2017. URL: https://www.semanticscholar.org/paper/7c8a2fdd2e9561c2569bc4e98397bbe347e630a2

[20] M. R. Lappin. Feline toxoplasmosis: interpretation of diagnostic test results. Seminars in Veterinary Medicine and Surgery, 1996. URL: https://www.semanticscholar.org/paper/0ebd1635960c3958e8d9abd8d2646094a8be6fd8

[21] A. Abdelbaset, Hend Alhasan, Doaa Salman et al. Evaluation of recombinant antigens in combination and single formula for diagnosis of feline toxoplasmosis. Experimental Parasitology, 2017. URL: https://www.semanticscholar.org/paper/1fd2239858e29ce336d8d273dd32e3c1ed51f467

[22] Özlem Günay-Esiyok, Ecem Su Koçkaya, Rana Yılmaz et al. The Potential of MIC17A both as an Entero-epithelial and Chronic Stage Marker for Detection of Feline Toxoplasmosis. Current Microbiology, 2026. URL: https://www.semanticscholar.org/paper/170f603aa98f7dd6b215d4a83f5f76f844c9e861

[23] J. Dubey. Feline toxoplasmosis and its nematode transmission. Journal, 1968. URL: https://www.semanticscholar.org/paper/9739e9c0ebc5b4da8a73d718ce795f65831c9bd1

[24] M. Lappin, C. Greene, S. Winston et al. Clinical feline toxoplasmosis. Serologic diagnosis and therapeutic management of 15 cases. Journal of Veterinary Internal Medicine, 1989. URL: https://www.semanticscholar.org/paper/188e9c3e7b48fcd3dd733c4dadbdd3bf4a2c1dbf

[25] M. Svoboda, J. Konrád, V. Svobodová. [Diagnosis and prevention of feline toxoplasmosis]. Tierarztliche Praxis, 1988. URL: https://www.semanticscholar.org/paper/0c47806d4447df5d683949639d6bc30766a7b03b

[26] A. Brennan. Risk factors in feline toxoplasmosis. Journal, 2018. URL: https://www.semanticscholar.org/paper/f488897999e2e89707722c6d17b4288f318c47a5

[27] J. L. Faria, C. Couto, Sheron L Wierzynski et al. Feline Toxoplasmosis: Tumor Necrosis Factor, Nitric Oxide, and Free Radicals in Seropositive Cats. Journal of Parasitology, 2018. URL: https://www.semanticscholar.org/paper/6949c8c0034df3c74f48a543ed58094bbdee2c85

[28] J. Dubey, J. K. Frenkel. Immunity to Feline Toxoplasmosis: Modification by Administration of Corticosteroids. Veterinary Pathology-Supplement, 1974. URL: https://www.semanticscholar.org/paper/7d02cb1226cf6abea11de16a6dd851250bc20241

[29] M. Petrak, J. Carpenter. FELINE TOXOPLASMOSIS. Journal of the American Veterinary Medical Association, 1965. URL: https://www.semanticscholar.org/paper/b716bfc934da864c863f7e5d8c3624e2dcc7c73e

[30] MacKnight Kt, Robinson Hw. Epidemiologic studies on human and feline toxoplasmosis. Journal, 1992. URL: https://www.semanticscholar.org/paper/1f00a302a974f5cfc4ddec180eb6d4e0e52698df

[31] S. P. Pakes, W. Lai. Carbon immunoassay-a simple and rapid serodiagnostic test for feline toxoplasmosis. Laboratory Animal Science, 1985. URL: https://www.semanticscholar.org/paper/080360020a814df09eb4c1d8667765bf1f9c6448

[32] T. Sivkova, A. Shchukina. [The epizootology of feline toxoplasmosis in the town of Perm]. Meditsinskaia Parazitologiia i Parazitarnye Bolezni, 2008. URL: https://www.semanticscholar.org/paper/676184d88f61d78d65e2295dde6078cb8874f7e8

[33] T. Hagiwara, Y. Katsube, T. Muto et al. Experimental feline toxoplasmosis. Nihon Juigaku Zasshi. The Japanese Journal of Veterinary Science, 1981. URL: https://www.semanticscholar.org/paper/4a9f71a86da7f23dbac805ed17582f5d491c5498

[34] K. Mizusawa, K. Oosawa, K. Thoyama et al. Seroepidemiological Survey on Feline Toxoplasmosis in Saitama Prefecture. Journal, 1991. URL: https://www.semanticscholar.org/paper/c614f887ae21d3ca12a82fdee2f1537273f48508

[35] M. Lappin. Chapter 28. Feline Toxoplasmosis. Journal, 2008. URL: https://www.semanticscholar.org/paper/0d5233dd99e8824d4e4e00369f97cc6b0491eefa *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.